Raymond James & Associates Infla Rx N.V. Transaction History
Raymond James & Associates
- $146 Billion
- Q1 2024
A detailed history of Raymond James & Associates transactions in Infla Rx N.V. stock. As of the latest transaction made, Raymond James & Associates holds 242,620 shares of IFRX stock, worth $422,158. This represents 0.0% of its overall portfolio holdings.
Number of Shares
242,620
Previous 175,279
38.42%
Holding current value
$422,158
Previous $285,000
30.88%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding IFRX
# of Institutions
40Shares Held
13.8MCall Options Held
12.9KPut Options Held
0-
Suvretta Capital Management, LLC New York, NY5.73MShares$9.98 Million0.38% of portfolio
-
Eversept Partners, LP New York, NY1.31MShares$2.27 Million0.15% of portfolio
-
Citigroup Inc1.2MShares$2.09 Million0.0% of portfolio
-
Morgan Stanley New York, NY979KShares$1.7 Million0.0% of portfolio
-
683 Capital Management, LLC New York, NY870KShares$1.51 Million0.11% of portfolio
About InflaRx N.V.
- Ticker IFRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 44,203,800
- Market Cap $76.9M
- Description
- InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...